🚨 Today, we're launching Axios Cities, a new once-weekly newsletter penned by Axios' own Kim Hart.
Today's word count is 826 words, or ~3 minutes.
Illustration: Sarah Grillo/Axios
The Affordable Care Act seems likely to suffer at least a few more legal setbacks on what appears to be its inevitable path back to the Supreme Court, Axios' Sam Baker reports from New Orleans.
The big picture: A pair of conservative judges kicked around several ideas for the ACA yesterday: Maybe they’d throw out the whole thing. Or maybe they’d punt it back to a lower-court judge — who previously threw out the whole thing. The one option that didn’t appear to be on the table was upholding it.
The most important question in this case is "severability" — whether the individual mandate can be excised from the ACA on its own.
But 5th Circuit Court of Appeals Judges Jennifer Elrod and Kurt Engelhardt pushed back forcefully against that idea yesterday.
Between the lines: The 5th Circuit is hearing an appeal from a decision by Judge Reed O’Connor, who said last year that the whole ACA must fall.
Yes, but: The 5th Circuit probably won't have the final say over the law's survival.
A group of senators is considering a plan to limit how much drug companies can raise their prices in Medicare's prescription drug benefit, among other changes.
The big picture: Some of the proposals would majorly restructure the way Medicare pays for drugs and are sure to draw massive industry pushback — if lawmakers can even agree to them.
Driving the news: Senate Finance Committee Chairman Chuck Grassley and the committee‘s top Democrat, Sen. Ron Wyden, have been negotiating a drug price package. Grassley briefed Republican members yesterday on the discussions.
Yes, but: Limiting price increases in Part D to the inflation rate is more controversial, as is a proposal to allow Medicaid to pay for gene therapies over time and tie payments to patient outcomes.
Administration officials, including HHS Secretary Alex Azar and the head of the Domestic Policy Council, Joe Grogan, attended yesterday's meeting.
Almost a quarter of traditional Medicare spending, or $114 billion, goes toward patients who have kidney disease, Axios' Bob Herman reports.
Why it matters: Kidney disease diagnoses are growing, especially among older adults. Because treating it requires a lot of discomfort and money, the Trump administration is pushing for policies that will encourage more people to get dialysis treatment at home instead of in clinics, Politico reports.
Hospices that were negligent to the point of patient harm went unpunished by Medicare, according to an HHS inspector general report covered by the Washington Post.
While Medicare covers most hospice care and the amount it spends on it is growing, its oversight of the care is weaker than its oversight of nursing homes.
Intense effort is underway to understand and prevent acute flaccid myelitis (AFM) by the Centers for Disease Control and Prevention, as the agency pushes doctors to report symptoms early, per its new Vital Signs report.
Why it matters: Doctors continue to seek the cause of the serious neurologic syndrome after the largest recorded outbreak in 2018 — 233 patients in 41 states reported symptoms that often included limb weakness or paralysis, my colleagues Marisa Fernandez and Eileen Drage O'Reilly write.
Editor's note: The second item in yesterday's Vitals used the wrong pronouns when referring to Judge Amit Mehta. He is a he. I apologize for the error.